
Nearly one in five HIV-positive women screened for cervical cancer at the Gujarat Cancer Research Institute (GCRI) have tested positive for human papillomavirus (HPV), with the programme also detecting one case of early-stage cervical cancer. Since the initiative began in March 2025, GCRI has screened 1,542 women at the Antiretroviral Therapy (ART) Centre at Ahmedabad’s Civil Hospital. Of those, 319 women, or 20.69%, tested HPV-positive, while 94 cases of cervical intraepithelial neoplasia were also found. The HPV positivity rate among these women was far above Gujarat’s general population rates of 4.82% (urban) and 5.22% (rural).

The initiative, which integrates cervical cancer screening into routine HIV care, has received the FICCI Healthcare Excellence Award 2026 in the patient care category. GCRI, jointly managed by the state government and the Gujarat Cancer Society, plans to extend the model to other ART centres across Gujarat, subject to feasibility and resource availability.
Both sources report the same figures from the Gujarat Cancer Research Institute (GCRI) screening programme, with no substantive difference in framing or omission. The coverage is uniform straight reporting, presenting the 20.69% HPV positivity rate among HIV-positive women, the single early-stage cancer detected, and the FICCI award as headline facts. Neither outlet adds commentary on government health policy or criticises the programme’s scope. The shared news value lies in the contrast between the HIV-positive cohort’s HPV rate and the general population’s rate of about 5%, which the sources present as the story’s core finding. The state’s plan to extend the model to other ART centres, subject to feasibility, is the named next step.
Coverage: 2 sources, 2 neutral
Sources (2): yespunjab.com (neutral report), tripuratimes.com (neutral report)
This brief was synthesised by AI from the 2 sources linked above, so one read covers every framing they carry. Methodology and corrections.